145 related articles for article (PubMed ID: 31442332)
1. TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model.
Green AC; Lath D; Hudson K; Walkley B; Down JM; Owen R; Evans HR; Paton-Hough J; Reilly GC; Lawson MA; Chantry AD
J Bone Miner Res; 2019 Dec; 34(12):2311-2326. PubMed ID: 31442332
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
Nyman JS; Merkel AR; Uppuganti S; Nayak B; Rowland B; Makowski AJ; Oyajobi BO; Sterling JA
Bone; 2016 Oct; 91():81-91. PubMed ID: 27423464
[TBL] [Abstract][Full Text] [Related]
3. Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models.
Paton-Hough J; Tazzyman S; Evans H; Lath D; Down JM; Green AC; Snowden JA; Chantry AD; Lawson MA
J Bone Miner Res; 2019 May; 34(5):783-796. PubMed ID: 30320927
[TBL] [Abstract][Full Text] [Related]
4. Haploinsufficiency of endogenous parathyroid hormone-related peptide impairs bone fracture healing.
Wang YH; Qiu Y; Han XD; Xiong J; Chen YX; Shi HF; Karaplis A
Clin Exp Pharmacol Physiol; 2013 Nov; 40(11):715-23. PubMed ID: 23937065
[TBL] [Abstract][Full Text] [Related]
5. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-13 is required for osteocytic perilacunar remodeling and maintains bone fracture resistance.
Tang SY; Herber RP; Ho SP; Alliston T
J Bone Miner Res; 2012 Sep; 27(9):1936-50. PubMed ID: 22549931
[TBL] [Abstract][Full Text] [Related]
7. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
[TBL] [Abstract][Full Text] [Related]
8. Exogenous PTHrP Repairs the Damaged Fracture Healing of PTHrP+/- Mice and Accelerates Fracture Healing of Wild Mice.
Wang Y; Fang X; Wang C; Ding C; Lin H; Liu A; Wang L; Cao Y
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178186
[TBL] [Abstract][Full Text] [Related]
9. A functional three-dimensional microphysiological human model of myeloma bone disease.
Visconti RJ; Kolaja K; Cottrell JA
J Bone Miner Res; 2021 Oct; 36(10):1914-1930. PubMed ID: 34173283
[TBL] [Abstract][Full Text] [Related]
10. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
[TBL] [Abstract][Full Text] [Related]
11. Impact of growth factors and PTHrP on early and late chondrogenic differentiation of human mesenchymal stem cells.
Weiss S; Hennig T; Bock R; Steck E; Richter W
J Cell Physiol; 2010 Apr; 223(1):84-93. PubMed ID: 20049852
[TBL] [Abstract][Full Text] [Related]
12. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
Lath DL; Buckle CH; Evans HR; Fisher M; Down JM; Lawson MA; Chantry AD
PLoS One; 2018; 13(6):e0199517. PubMed ID: 29924867
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.
Lu A; Pallero MA; Lei W; Hong H; Yang Y; Suto MJ; Murphy-Ullrich JE
Am J Pathol; 2016 Mar; 186(3):678-90. PubMed ID: 26801735
[TBL] [Abstract][Full Text] [Related]
14. Periosteal PTHrP Regulates Cortical Bone Remodeling During Fracture Healing.
Wang M; Nasiri AR; Broadus AE; Tommasini SM
Bone; 2015 Dec; 81():104-111. PubMed ID: 26164475
[TBL] [Abstract][Full Text] [Related]
15. TGFβ-2 signaling is essential for osteoblast migration and differentiation during fracture healing in medaka fish.
Takeyama K; Chatani M; Inohaya K; Kudo A
Bone; 2016 May; 86():68-78. PubMed ID: 26947892
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
[TBL] [Abstract][Full Text] [Related]
17. Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone.
Biswas S; Nyman JS; Alvarez J; Chakrabarti A; Ayres A; Sterling J; Edwards J; Rana T; Johnson R; Perrien DS; Lonning S; Shyr Y; Matrisian LM; Mundy GR
PLoS One; 2011; 6(11):e27090. PubMed ID: 22096521
[TBL] [Abstract][Full Text] [Related]
18. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
19. Response to bortezomib and activation of osteoblasts in multiple myeloma.
Zangari M; Yaccoby S; Cavallo F; Esseltine D; Tricot G
Clin Lymphoma Myeloma; 2006 Sep; 7(2):109-14. PubMed ID: 17026821
[TBL] [Abstract][Full Text] [Related]
20. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.
Garcia-Gomez A; Quwaider D; Canavese M; Ocio EM; Tian Z; Blanco JF; Berger AJ; Ortiz-de-Solorzano C; Hernández-Iglesias T; Martens AC; Groen RW; Mateo-Urdiales J; Fraile S; Galarraga M; Chauhan D; San Miguel JF; Raje N; Garayoa M
Clin Cancer Res; 2014 Mar; 20(6):1542-54. PubMed ID: 24486586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
